N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, announces the initial findings from analysing the preliminary results of the pharmacokinetic (“PK”) data from its clinical trial for the reformulation of sildenafil.
Whilst the Company is yet to receive the full results from the clinical trial, it is clear from the preliminary PK data that the current formulation has not met the key target endpoints of the trial. To that end, the product formulation will need to be reviewed to assess what changes would be required to make the reformulated drug viable in the context of the Company’s patent position.
Nigel Theobald, CEO of N4 Pharma, commented: “This part of the process of drug reformulation is always going to be a challenge and whilst this preliminary data is clearly disappointing, we will need to see the full set of results expected around the end of August to understand the detailed implications for the formulation. We will provide a further update once we have had a chance to review all the findings from the trial about the next steps we will take to reformulate the product.
“Our nuvec® development program continues as planned and as advised earlier we will release further news on these results in Q4 of this year.”